Targeting Therapies for the p53 Protein in Cancer Treatments

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995

Ferroptosis as a p53-mediated activity during tumour suppression

Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113

Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53

Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562

Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations

Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · cited 2×

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206

Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas

Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,097

The p53 proto-oncogene can act as a suppressor of transformation

Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987

Putting p53 in context

Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814

The p53-mdm-2 autoregulatory feedback loop.

Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598

Control of apoptosis by p53

Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401

The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes

Levine, A. J., & Puzio-Kuter, A. M. (2010) · Science · doi:10.1126/science.1193494 · Cited by 1,243

High-throughput functional genomics using CRISPR-Cas9

Shalem, O., Sanjana, N. E., & Zhang, F. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3899 · Cited by 1,233

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191

p53- and ATM-Dependent Apoptosis Induced by Telomeres Lacking TRF2

Karlseder, J., Broccoli, D., Dai, Y., Hardy, S., & de Lange, T. (1999) · Science · doi:10.1126/science.283.5406.1321 · Cited by 1,086

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

Heise, C. C., Sampson-Johannes, A., Williams, A., McCormick, F. P., Hoff, D. D. V., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 941

Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

Kato, S., Han, S., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 895

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894

UV Irradiation Stimulates Levels of p53 Cellular Tumor Antigen in Nontransformed Mouse Cells

Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865

Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells

Sarnow, P., Ho, Y.-S., Williams, J., & Levine, A. J. (1982) · Cell · doi:10.1016/0092-8674(82)90356-7 · Cited by 836

Pharmacological Rescue of Mutant p53 Conformation and Function

Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802

TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data: Human Mutation

Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

DeLeo, A. B., Jay, G. D., Appella, E., DuBois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721

Wild-type p53 can inhibit oncogene-mediated focus formation.

Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., & Oren, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8763 · Cited by 687

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A.-T., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 655

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint

Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652

Why are there hotspot mutations in the TP53 gene in human cancers?

Baugh, E. H., Ke, H., Levine, A. J., Bonneau, R., & Chan, C. S. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.180 · Cited by 609

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592

Signaling to p53: ribosomal proteins find their way

Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517

Autophagy regulation by p53

Maiuri, M. C., Galluzzi, L., Morselli, E., Kepp, O., Malik, S. A., & Kroemer, G. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.12.001 · Cited by 515

Identification of a novel p53 functional domain that is necessary for efficient growth suppression

Walker, K. K., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15335 · Cited by 477

The Tumor Suppressor p53: From Structures to Drug DiscoveryPreprint

Joerger, A. C., & Fersht, A. R. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000919 · Cited by 380

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 368

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 359

Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods

Mathé, E. A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj518 · Cited by 340

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336

Allele-Specific p53 Mutant Reactivation

Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 321

Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

Hanel, W. G., Marchenko, N. D., Xu, S., Yu, S., Weng, W., & Moll, U. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.17 · Cited by 278

Reciprocal influence of the p53 and the hypoxic pathways

Sermeus, A., & Michiels, C. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.48 · Cited by 278

Paradoxical suppression of cellular senescence by p53

Demidenko, Z. N., Korotchkina, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002298107 · Cited by 273

Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome

Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 268

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261

Somatic TP53 Mutations in the Era of Genome SequencingPreprint

Hainaut, P. L., & Pfeifer, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026179 · Cited by 256

Small molecule induced reactivation of mutant p53 in cancer cells

Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 246

Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines.

Hinds, P. W., Finlay, C. A., Frey, A. B., & Levine, A. J. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2863 · Cited by 232

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Li, L., Hoog, J., Goiffon, R., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 227

Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene

Chen, J., Lin, J., & Levine, A. J. (1995) · Molecular Medicine · doi:10.1007/bf03401562 · Cited by 214

Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways

Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222406899 · Cited by 210

A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation

Lutzker, S. G., & Levine, A. J. (1996) · Nature Medicine · doi:10.1038/nm0796-804 · Cited by 206

GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity

Jin, S., Tong, T., Fan, W., Fan, F., Antinore, M. J., Zhu, X., Mazzacurati, L., Li, X., Petrik, K. L., Rajasekaran, B., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1206034 · Cited by 205

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202

Regulation of p53 Tumor Suppressor by Helicobacter pylori in Gastric Epithelial Cells

Wei, J., Nagy, T. A., Vilgelm, A. E., Zaika, E. I., Ogden, S. R., Romero–Gallo, J., Piazuelo, M. B., Correa, P., Washington, M. K., El-Rifai, W. M., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.018 · Cited by 190

Mutant p53 reactivation by small molecules makes its way to the clinic

Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 181

Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations

Joerger, A. C., Ang, H. C., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500179200 · Cited by 181

The Transactivation Domains of the p53 ProteinPreprint

Raj, N., & Attardi, L. D. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026047 · Cited by 178

Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations

Nikolova, P. V., Wong, K., DeDecker, B. S., Henckel, J., & Fersht, A. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.370 · Cited by 173

Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy

Vogel, C., Kienitz, A., Hofmann, I., Müller, R., & Bastians, H. (2004) · Oncogene · doi:10.1038/sj.onc.1207860 · Cited by 171

p53 regulation of DNA excision repair pathways

Smith, M. L. (2002) · Mutagenesis · doi:10.1093/mutage/17.2.149 · Cited by 164

Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

Brachmann, R. K., Yu, K., Eby, Y. J., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 157

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53

Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm099 · Cited by 145

Copper-Binding Small Molecule Induces Oxidative Stress and Cell Cycle Arrest in Glioblastoma-Patient-Derived Cells

Shimada, K., Reznik, E., Stokes, M. E., Krishnamoorthy, L., Bos, P. H., Song, Y., Quartararo, C. E., Pagano, N. C., Carpizo, D. R., deCarvalho, A. C., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.02.010 · Cited by 121

Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277

Buzek, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.11.2340 · Cited by 118

Interactions between the tumor suppressor p53 and immune responses

Menéndez, D., Shatz, M., & Resnick, M. A. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835b6386 · Cited by 115

Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism

Yu, X., Blanden, A. R., Narayanan, S., Jayakumar, L., Lubin, D. J., Augeri, D. J., Kimball, S. D., Loh, S. N., & Carpizo, D. R. (2014) · Oncotarget · doi:10.18632/oncotarget.2432 · Cited by 111

Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo

Lee, M. K., Teoh, W. W., Phang, B. H., Tong, W., Wang, Z. Q., & Sabapathy, K. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.022 · Cited by 104

The Inherited p53 Mutation in the Brazilian PopulationPreprint

Achatz, M. I., & Zambetti, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026195 · Cited by 99

Identification of potential synthetic lethal genes to p53 using a computational biology approach

Wang, X., & Simon, R. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-30 · Cited by 91

Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore

Blanden, A. R., Yu, X., Wolfe, A. J., Gilleran, J., Augeri, D. J., O’Dell, R. S., Olson, E. C., Kimball, S. D., Emge, T. J., Movileanu, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097550 · Cited by 86

Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3

Baldwin, A. E., Grueneberg, D. A., Hellner, K., Sawyer, J., Grace, M. R., Li, W., Harlow, E., & Münger, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007462107 · Cited by 83

MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and BeyondPreprint

Marine, J., & Jochemsen, A. G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026237 · Cited by 82

The Paradox of p53: What, How, and Why?Preprint

Aylon, Y., & Oren, M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026328 · Cited by 81

Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions

Eldar, A., Rozenberg, H., Diskin‐Posner, Y., Rohs, R., & Shakked, Z. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt630 · Cited by 77

Lysine methylation represses p53 activity in teratocarcinoma cancer cells

Zhu, J., Dou, Z., Sammons, M. A., Levine, A. J., & Berger, S. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610387113 · Cited by 44

The screening of the second‐site suppressor mutations of the common p53 mutants

Otsuka, K., Kato, S., Kakudo, Y., Mashiko, S., Shibata, H., & Ishioka, C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22724 · Cited by 28

Pharmacological targeting of mutant p53

Kogan, S., & Carpizo, D. R. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.74 · Cited by 24

Role of tumor suppressor genes in transplacental lung carcinogenesis

Rollins, L. A., Leone‐Kabler, S., O’Sullivan, M. G., & Miller, M. S. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199803)21:3 · Cited by 23

Anin silicoalgorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein

Bromley, D., Bauer, M. R., Fersht, A. R., & Daggett, V. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzw035 · Cited by 16

p53 as an Effector or Inhibitor of Therapy ResponsePreprint

Ablain, J., Poirot, B., Esnault, C., Lehmann‐Che, J., & de Thé, H. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026260 · Cited by 15

p53 in cancer: ready for therapeutic targeting?

Duffy, M. J., Synnott, N. C., & Crown, J. P. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.45 · Cited by 10

Targeting apoptosis in cancer therapy

Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,676

p53: 800 million years of evolution and 40 years of discovery

Levine, A. J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 876

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 576

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396

Targeting p53 for the treatment of cancer

Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 355

Review of mutant p53 protein and the p53 targeting therapy in cancer treatment

Yin, Y. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/16/20240550

Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies

Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer

Zhang, S., Carlsen, L., Borrero, L. J. H., Seyhan, A. A., Tian, X., & El‐Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 75

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 251